El Salvador vs Guinea: Average cost of multi drug-resistant tuberculosis treatment
El Salvador
574 constant 2022 US$
in 2024
Guinea
616 constant 2022 US$
in 2024
El Salvador rank
73rd
Guinea rank
71st
Average cost of multi drug-resistant tuberculosis treatment over time
- El Salvador
- Guinea
How they compare
Guinea currently reports 616 constant 2022 US$ against 574 constant 2022 US$ in El Salvador, a difference of 42 constant 2022 US$.
That makes Guinea's figure about 1.1 times El Salvador's.
The two have swapped places 3 times across 8 shared years of data; in 2017 it was El Salvador ahead.
El Salvador ranks 73rd and Guinea ranks 71st of 92 countries.
El Salvador has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | El Salvador | Guinea | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,590 constant 2022 US$ | 527 constant 2022 US$ | 1,063 constant 2022 US$ | El Salvador |
| 2020s | 3,208 constant 2022 US$ | 1,127 constant 2022 US$ | 2,081 constant 2022 US$ | El Salvador |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, El Salvador or Guinea?
- Guinea, at 616 constant 2022 US$ against 574 constant 2022 US$ in El Salvador as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between El Salvador and Guinea?
- 42 constant 2022 US$, with Guinea ahead.
- How many years of comparable data are there for El Salvador and Guinea?
- 8 years are reported by both, from 2017 to 2024.
- How do El Salvador and Guinea rank globally for average cost of multi drug-resistant tuberculosis treatment?
- El Salvador ranks 73rd and Guinea ranks 71st of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.